Patent intelligence · US
US 12012597
Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein
Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein
Patent details — US 12012597
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 18, 2024
- Expiration
- Jun 13, 2044
- Applicant
- ARIZ Precision Medicine, Inc.
- Claims
- 8
- CPC classes
- A61P, A61P35/00
Quick answer
US 12012597 (Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein) is held by ARIZ Precision Medicine, Inc.. Status: granted. Granted Jun 18, 2024. Expires Jun 13, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARIZ Precision Medicine, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61P, A61P35/00
More from ARIZ Precision Medicine, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 12012597?
US 12012597 (Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein) is held by ARIZ Precision Medicine, Inc.. Status: granted. Granted Jun 18, 2024. Expires Jun 13, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12012597?
ARIZ Precision Medicine, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 12012597 expire?
Our index shows an expiration date of Jun 13, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.